TGN1412 and PMOA –Story of a monoclonal antibody that did the unexpected
Update: 2021-03-23
Description
In this episode, Diane and I are joined by Husain Attarwala, Head of Pharmacometrics and Clinical Pharmacology at Moderna and author of a paper diving into the 2006 failed clinical trial of TGN1412. We discuss how things went wrong, and what to consider when planning clinical trials to help keep study participants safe.
Kelly Creighton, VP for Regulatory and Strategic Development at Clinipace also joins us to discuss the importance of understanding the Primary Mechanism of Action (PMOA) of biologics and FDA expectations.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
